Viruses

R+D Custom Automation Has Announced an Agreement with SiO2 Materials Science

Retrieved on: 
Thursday, July 9, 2020

LAKE VILLA, Ill., July 9, 2020 /PRNewswire/ --R+D Custom Automation, a privately-owned U.S. provider of fully customized automation systems, has announced an agreement with SiO2 Materials Science.

Key Points: 
  • LAKE VILLA, Ill., July 9, 2020 /PRNewswire/ --R+D Custom Automation, a privately-owned U.S. provider of fully customized automation systems, has announced an agreement with SiO2 Materials Science.
  • SiO2, a privately-owned U.S. advanced materials science corporation, was recently awarded a $143 million contract with the federal government as part of the Operation Warp Speed initiative.
  • The agreement accelerates the production of SiO2's patented plastic vials for storing novel coronavirus (SARS-CoV-2) vaccines and therapeutics.
  • According to Lawrence Ganti, President of Customer Operations at SiO2, the SiO2 vials are the only alternative to glass.

CENTOGENE Announces the Scientific Publication of a holistic solution in the preventive testing of COVID-19

Retrieved on: 
Thursday, July 9, 2020

The paper describes innovative testing solutions in the fight against COVID-19 pandemic and contributes to the global understanding of the novel Coronavirus.

Key Points: 
  • The paper describes innovative testing solutions in the fight against COVID-19 pandemic and contributes to the global understanding of the novel Coronavirus.
  • Furthermore, it discusses the Companys science-backed Coronavirus initiatives, and how these can provide a testing blueprint for the medical community.
  • The holistic solution is also the basis for our service to airport based mobility, like at the Frankfurt airport.
  • CENTOGENE Contact: Ben Legg Corporate Communications [email protected] Media Contact: FTI Consulting Bridie Lawlor +1.917.929.5684 [email protected]

ChromaDex Announces New Study Results Highlighting Promising Anti-Viral Effects of Niagen® in Coronavirus Cell Model

Retrieved on: 
Thursday, July 9, 2020

These latest results confirmed their hypothesis by demonstrating that cell lines infected with a type of Coronavirus had decreased viral replication when supplemented with NR.

Key Points: 
  • These latest results confirmed their hypothesis by demonstrating that cell lines infected with a type of Coronavirus had decreased viral replication when supplemented with NR.
  • The collaborative research team also found that the activity of antiviral PARP enzymes was upregulated by boosting NAD pharmacologically.
  • The next steps are animal and human trials against SARS-CoV-2, reports Dr. Charles Brenner, a co-author of the study and ChromaDex Chief Scientific Advisor.
  • The team of investigators used a multi-pronged approach involving a form of Coronavirus and performed experiments in multiple separate cell models.

Applied DNA Forms Clinical Testing Subsidiary to Maximize Utility of FDA EUA-Approved Linea™ COVID-19 Assay Kit and Expands Utility with Successful EUA Amendment

Retrieved on: 
Thursday, July 9, 2020

In mid-May, Applied DNA received Emergency Use Authorization (EUA) for a high sensitivity, high-throughput complex molecular test for SARS-CoV-2, the coronavirus that causes COVID-19.

Key Points: 
  • In mid-May, Applied DNA received Emergency Use Authorization (EUA) for a high sensitivity, high-throughput complex molecular test for SARS-CoV-2, the coronavirus that causes COVID-19.
  • The Linea COVID-19 SARS-CoV-2 Assay Kit is a real-time polymerase chain reaction (RT-PCR) test for the qualitative detection of SARS-CoV-2 RNA in respiratory specimens.
  • It provides a high-throughput solution to help laboratories address the urgent need for patient testing during the Coronavirus pandemic.
  • ADCL, the Companys new subsidiary was formed to enable clinical testing of patient specimens using methods developed by the Companys research teams.

UK Real Estate Company Hondo Enterprises in Partnership With Savills to Use BioProtectUs™ System in United Kingdom

Retrieved on: 
Thursday, July 9, 2020

LONDON, July 9, 2020 /PRNewswire/ --Hondo Enterprises, in partnership with Savills, has become the first and only company in the United Kingdom to utilise the BIOPROTECTUs system offered by BioSupplies.com, LLC in the United Kingdom.

Key Points: 
  • LONDON, July 9, 2020 /PRNewswire/ --Hondo Enterprises, in partnership with Savills, has become the first and only company in the United Kingdom to utilise the BIOPROTECTUs system offered by BioSupplies.com, LLC in the United Kingdom.
  • The system, which features a water-based anti-microbial called BIOPROTECT, was independently verified by a third party to eradicate SARS-CoV-2 from surfaces for more than six weeks.
  • SARS-CoV-2 is the unique coronavirus that causes COVID-19.
  • Hondo Enterprises is a property investment, development and asset management company specialising in transactions in Central London.

UK Real Estate Company Hondo Enterprises in Partnership With Savills to Use BioProtectUs™ System in United Kingdom

Retrieved on: 
Thursday, July 9, 2020

LONDON, July 9, 2020 /PRNewswire/ --Hondo Enterprises, in partnership with Savills, has become the first and only company in the United Kingdom to utilise the BIOPROTECTUs system offered by BioSupplies.com, LLC in the United Kingdom.

Key Points: 
  • LONDON, July 9, 2020 /PRNewswire/ --Hondo Enterprises, in partnership with Savills, has become the first and only company in the United Kingdom to utilise the BIOPROTECTUs system offered by BioSupplies.com, LLC in the United Kingdom.
  • The system, which features a water-based anti-microbial called BIOPROTECT, was independently verified by a third party to eradicate SARS-CoV-2 from surfaces for more than six weeks.
  • SARS-CoV-2 is the unique coronavirus that causes COVID-19.
  • Hondo Enterprises is a property investment, development and asset management company specialising in transactions in Central London.

Novel Coronavirus (COVID-19) Pipeline Guide 2020: Therapeutics Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type

Retrieved on: 
Wednesday, July 8, 2020

This pipeline guide provides an overview of the Coronavirus Disease 2019 (COVID-19) (Infectious Disease) pipeline landscape.

Key Points: 
  • This pipeline guide provides an overview of the Coronavirus Disease 2019 (COVID-19) (Infectious Disease) pipeline landscape.
  • The guide provides comprehensive information on the therapeutics under development for Coronavirus Disease 2019 (COVID-19) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The pipeline guide reviews key companies involved in Coronavirus Disease 2019 (COVID-19) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Coronavirus Disease 2019 (COVID-19) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

CytoDyn to Present at Wall Street Reporter’s Livestream Event on July 9, 2020 at 1:30 pm ET / 10:30 am PT

Retrieved on: 
Wednesday, July 8, 2020

SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China.

Key Points: 
  • SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China.
  • COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact.
  • Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals.
  • The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases.

LI-COR Near-Infrared Assays and Technology Offer Insight to Coronavirus Researchers

Retrieved on: 
Tuesday, July 7, 2020

Key to this process are quantifiable assays that provide robust data for all aspects of research.

Key Points: 
  • Key to this process are quantifiable assays that provide robust data for all aspects of research.
  • LI-CORBiosciences continues to support virology researchers with products, tools, and services to better understand SARS-CoV-2 and other viruses.
  • Traditionally, infectivity of viruses that exhibit cytopathic effect (CPE) has been characterized using plaque assays.
  • From academic discovery through preclinical validation, whether characterizing a pathway or validating a therapeutic candidate, LI-COR technology helps move research through the development process.

CytoDyn’s Leronlimab Prevents Transmission of SHIV in Macaque Study

Retrieved on: 
Tuesday, July 7, 2020

The study evaluated the impact of a macaque-equivalent dose of either 350 mg (once weekly) or 700 mg (bi-monthly) leronlimab on acquisition of infection in a total of 18 animals, and found that the equivalent 700 mg bi-monthly leronlimab dose completely prevented rectal transmission of Simian-Human Immunodeficiency Virus (SHIV) in macaques.

Key Points: 
  • The study evaluated the impact of a macaque-equivalent dose of either 350 mg (once weekly) or 700 mg (bi-monthly) leronlimab on acquisition of infection in a total of 18 animals, and found that the equivalent 700 mg bi-monthly leronlimab dose completely prevented rectal transmission of Simian-Human Immunodeficiency Virus (SHIV) in macaques.
  • Coupled with its safety profile, leronlimab could offer a much needed simple and long-lasting preventative treatment option for people at risk of HIV infection, concluded Dr. Pourhassan.
  • The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases.
  • Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans.